




Edition: BP 2025 (Ph. Eur. 11.6 update)

Methylergometrine Maleate



[General Notices](#)

(Ph. Eur. monograph 1788)



$C_{24}H_{29}N_3O_6$ 455.5 57432-61-8

Action and use

Oxytocic.

Ph Eur

DEFINITION

(6a*R*,9*R*)-*N*-[(1*S*)-1-(Hydroxymethyl)propyl]-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-*fg*]quinoline-9-carboxamide (*Z*)-butenedioate.

Content

99.0 per cent to 101.0 per cent (dried substance).

CHARACTERS

Appearance

White or almost white, hygroscopic, crystalline powder.

Solubility

Soluble in water, slightly soluble in anhydrous ethanol.

IDENTIFICATION

- A. Specific optical rotation (see Tests).
B. Infrared absorption spectrophotometry ([2.2.24](#)).

Comparison [methylephedrine maleate CRS](#).

TESTS

Solution S

Dissolve 0.100 g in [carbon dioxide-free water R](#) and dilute to 20.0 mL with the same solvent.

pH ([2.2.3](#))

4.4 to 5.2.

Dilute 2.0 mL of solution S to 50.0 mL with [carbon dioxide-free water R](#).

Specific optical rotation ([2.2.7](#))

+ 44.0 to + 50.0 (dried substance), determined on solution S.

Related substances

Liquid chromatography ([2.2.29](#)). Carry out the test protected from light.

Test solution Dissolve 25 mg of the substance to be examined in 15 mL of mobile phase B and dilute to 50.0 mL with [water R](#).

Reference solution (a) Dilute 1.0 mL of the test solution to 100.0 mL with [water R](#). Dilute 1.0 mL of this solution to 10.0 mL with [water R](#).

Reference solution (b) Dissolve the contents of a vial of [methylephedrine for system suitability CRS](#) (containing impurities A, B, C, D, E, F, G, H and I) in 1.0 mL of a mixture of 30 volumes of mobile phase B and 70 volumes of [water R](#).

Column:

— size: $l = 0.10$ m, $\varnothing = 4.6$ mm;

— stationary phase: [end-capped octadecylsilyl silica gel for chromatography R](#) (3.5 μ m).

Mobile phase:

— mobile phase A: 2 g/L solution of [ammonium carbamate R](#);

— mobile phase B: [acetonitrile R](#), [water R](#) (50:50 V/V);

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 2	85	15

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
2 - 7	85 → 65	15 → 35
7 - 12	65	35
12 - 17	65 → 20	35 → 80
17 - 19	20	80

Flow rate 2.0 mL/min.

Detection Spectrophotometer at 310 nm.

Injection 20 µL.

Identification of impurities Use the chromatogram supplied with [methylephedrine for system suitability CRS](#) and the chromatogram obtained with reference solution (b) to identify the peaks due to impurities A, B, C, D, E, F, G, H and I.

Relative retention With reference to methylephedrine (retention time = about 12 min):
 impurity A = about 0.2; impurity B = about 0.5; impurity C = about 0.6; impurity D = about 0.7;
 impurity I = about 1.10; impurity E = about 1.14; impurity F = about 1.2; impurity G = about 1.3;
 impurity H = about 1.4.

System suitability Reference solution (b):

— *resolution*: minimum 3.0 between the peaks due to methylephedrine and impurity I; minimum 1.5 between the peaks due to impurities I and E.

Limits:

— *impurity I*: not more than 3 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.3 per cent);

— *impurity C*: not more than twice the area of the principal peak in the chromatogram obtained with reference solution (a) (0.2 per cent);

— *impurities A, B, D, E, F, G, H*: for each impurity, not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.15 per cent);

— *unspecified impurities*: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.10 per cent);

— *total*: not more than 6 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.6 per cent);

— *disregard limit*: 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.05 per cent).

Loss on drying (2.2.32)

Maximum 2.0 per cent, determined on 1.000 g by drying in an oven at 105 °C.

Sulfated ash (2.4.14)

Maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Dissolve 0.300 g in 60 mL of [anhydrous acetic acid R](#). Titrate with [0.1 M perchloric acid](#), determining the end-point potentiometrically ([2.2.20](#)).


1 mL of [0.1 M perchloric acid](#) is equivalent to 45.55 mg of $C_{24}H_{29}N_3O_6$.

STORAGE


In an airtight container, protected from light.

IMPURITIES


Specified impurities A, B, C, D, E, F, G, H, I.




A. (6aR,9R)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxylic acid,




B. (6aR,9S)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxylic acid,




C. (6aR,9R)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide,




D. (6aR,9R)-N-[(1S)-2-hydroxy-1-methylethyl]-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (ergometrine),




E. (6a*R*,9*S*)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-*fg*]quinoline-9-carboxamide,




F. (6a*R*,9*S*)-*N*-[(1*S*)-2-hydroxy-1-methylethyl]-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-*fg*]quinoline-9-carboxamide (ergometrine),



G. (6a*R*,9*R*)-*N*-[(1*S*)-1-(hydroxymethyl)propyl]-4,7-dimethyl-4,6,6a,7,8,9-hexahydroindolo[4,3-*fg*]quinoline-9-carboxamide (methysergide),



H. (6a*R*,9*S*)-*N*-[(1*S*)-1-(hydroxymethyl)propyl]-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-*fg*]quinoline-9-carboxamide (methylergometrine),



I. (6a*R*,9*R*)-*N*-[(1*R*)-1-(hydroxymethyl)propyl]-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-*fg*]quinoline-9-carboxamide (1'-*epi*-methylergometrine).

